Total Payments
$108,386
2024 Payments
$21,468
Companies
17
Transactions
108
Medicare Patients
784
Medicare Billing
$68,141
Payment Breakdown by Category
Consulting$77,959 (71.9%)
Other$13,065 (12.1%)
Research$9,678 (8.9%)
Food & Beverage$3,387 (3.1%)
Travel$3,047 (2.8%)
Education$1,250 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $77,959 | 37 | 71.9% |
| Honoraria | $10,230 | 5 | 9.4% |
| Unspecified | $9,678 | 15 | 8.9% |
| Food and Beverage | $3,387 | 37 | 3.1% |
| Travel and Lodging | $3,047 | 12 | 2.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,835 | 1 | 2.6% |
| Education | $1,250 | 1 | 1.2% |
Payments by Type
General
$98,708
93 transactions
Research
$9,678
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $14,505 | 15 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $14,080 | 23 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $13,940 | 12 | $0 (2019) |
| Advanced Accelerator Applications | $13,818 | 5 | $0 (2020) |
| Amryt Pharma Holdings Ltd | $13,000 | 6 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $12,840 | 16 | $0 (2024) |
| TerSera Therapeutics LLC | $9,603 | 6 | $0 (2021) |
| Ipsen Bioscience Inc | $5,220 | 1 | $0 (2020) |
| AbbVie, Inc. | $4,617 | 12 | $0 (2017) |
| LANTHEUS MEDICAL IMAGING, INC. | $2,835 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,468 | 21 | Exelixis Inc. ($14,505) |
| 2023 | $5,000 | 3 | Amryt Pharma Holdings Ltd ($5,000) |
| 2022 | $10,526 | 6 | Amryt Pharma Holdings Ltd ($8,000) |
| 2021 | $12,893 | 9 | TerSera Therapeutics LLC ($9,603) |
| 2020 | $22,187 | 14 | Advanced Accelerator Applications ($8,281) |
| 2019 | $13,898 | 12 | Lexicon Pharmaceuticals, Inc. ($8,038) |
| 2018 | $11,371 | 14 | Lexicon Pharmaceuticals, Inc. ($5,901) |
| 2017 | $11,044 | 29 | Novartis Pharmaceuticals Corporation ($6,399) |
All Payment Transactions
108 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $660.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $339.29 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 08/01/2024 | Exelixis Inc. | — | Honoraria | Cash or cash equivalent | $660.00 | General |
| 07/09/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,835.00 | General |
| 06/02/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $98.01 | General |
| Category: Oncology | ||||||
| 06/01/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $161.64 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 05/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $990.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/14/2024 | Abbott Laboratories | ETERNA (Device) | Food and Beverage | In-kind items and services | $43.44 | General |
| Category: RAPID DIAGNOSTICS | ||||||
| 04/01/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $112.44 | General |
| Category: Oncology | ||||||
| 03/07/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $5,280.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $468.20 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $299.79 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $97.58 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $55.15 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/29/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $175.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/09/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Consulting Fee | Cash or cash equivalent | $3,712.50 | General |
| Category: Oncology | ||||||
| 01/25/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $2,640.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/17/2023 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Endocrinology | ||||||
| 01/13/2023 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: Endocrinology | ||||||
| 01/13/2023 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Endocrinology | ||||||
| 12/15/2022 | Progenics Pharmaceuticals, Inc. | AZEDRA (Drug) | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,178 | 14 |
| A COMPARISON OF ENTRESTO VALSARTAN SACUBITRIL AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ACEI UTILIZATION AMONG VETERANS WITH HEART FAILURE AND REDUCED EJECTION FRACTION | NOVARTIS PHARMACEUTICALS CORPORATION | $1,500 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 170 | 198 | $52,856 | $13,681 |
| 2022 | 4 | 181 | 204 | $58,214 | $15,823 |
| 2021 | 5 | 200 | 234 | $68,691 | $20,151 |
| 2020 | 6 | 233 | 299 | $74,536 | $18,486 |
Total Patients
784
Total Services
935
Medicare Billing
$68,141
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 85 | 109 | $28,938 | $7,794 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 61 | 65 | $11,189 | $3,230 | 28.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 24 | $12,729 | $2,657 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 90 | 103 | $26,216 | $7,785 | 29.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 29 | $14,913 | $3,469 | 23.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 53 | 58 | $9,571 | $2,968 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 14 | 14 | $7,514 | $1,601 | 21.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 118 | 146 | $35,701 | $11,343 | 31.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 28 | 32 | $15,828 | $3,759 | 23.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $11,966 | $3,516 | 29.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 20 | 21 | $3,300 | $973.24 | 29.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 11 | 12 | $1,896 | $560.10 | 29.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 91 | 127 | $29,798 | $7,457 | 25.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 79 | 103 | $15,666 | $4,035 | 25.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 24 | 24 | $12,102 | $3,368 | 27.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 18 | $8,513 | $1,639 | 19.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 14 | 14 | $6,536 | $1,431 | 21.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 13 | 13 | $1,921 | $555.88 | 28.9% |
About Dr. Daniel Halperin, MD
Dr. Daniel Halperin, MD is a Medical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2009. The National Provider Identifier (NPI) number assigned to this provider is 1801024161.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Halperin, MD has received a total of $108,386 in payments from pharmaceutical and medical device companies, with $21,468 received in 2024. These payments were reported across 108 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($77,959).
As a Medicare-enrolled provider, Halperin has provided services to 784 Medicare beneficiaries, totaling 935 services with total Medicare billing of $68,141. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Houston, TX
- Active Since 06/25/2009
- Last Updated 06/09/2015
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1801024161
Products in Payments
- CABOMETYX (Drug) $13,845
- Xermelo (Drug) $13,311
- MYCAPSSA (Drug) $13,000
- LUTATHERA (Drug) $12,096
- SOMATULINE DEPOT (Drug) $11,059
- SANDOSTATIN (Drug) $8,178
- Lutathera (Drug) $5,537
- Quzyttir (Drug) $2,619
- AZEDRA (Drug) $2,300
- AFINITOR (Drug) $1,694
- Somatuline Depot (Drug) $1,571
- Detectnet (Drug) $1,100
- PYLARIFY (Drug) $161.64
- SANDOSTATIN LAR (Drug) $126.84
- Tazverik (Drug) $112.44
- Onivyde (Drug) $98.01
- Abraxane (Drug) $74.81
- ETERNA (Device) $43.44
- CGA-II (Device) $33.75
- PROCALCITONIN (Drug) $27.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Houston
Roy Herbst, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Putao Cen, Md, MD
Medical Oncology — Payments: $817,580
Medical Oncology $817,580
Hagop Kantarjian, Md, MD
Medical Oncology — Payments: $740,835
Medical Oncology $740,835
Dr. Matthew Ellis, Md Phd, MD PHD
Medical Oncology — Payments: $714,994
Medical Oncology $714,994
Eleni Efstathiou, M.d, M.D
Medical Oncology — Payments: $600,908
Medical Oncology $600,908
Srdan Verstovsek, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $577,763
Medical Oncology $577,763